← Back to Search

Anti-inflammatory agent

AZD9668 active treatment for Bronchiectasis (NEPAL Trial)

Phase 2
Waitlist Available
Led By Stockley, Prof
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up last 7 days on treatment

Summary

The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Bronchiectasis (Brx) and if so how it compares to placebo (a substance which does not have any action).

Eligible Conditions
  • Bronchiectasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~last 7 days on treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and last 7 days on treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
24-hour Sputum Weight(g)
Bronkotest Diary Card Signs and Symptoms
Evening Peak Expiratory Flow (PEF)
+8 more
Secondary study objectives
Ratio of Interleukin 1 Beta (IL-1β) at End of Treatment Compared to Baseline
Interleukins
Ratio of Interleukin 8 (IL-8) at End of Treatment Compared to Baseline
+6 more

Side effects data

From 2008 Phase 2 trial • 18 Patients • NCT00703391
17%
Back pain
8%
Respiratory tract infection
8%
Musculoskeletal pain
8%
Headache
8%
Hyperhidrosis
8%
Palpitations
8%
Diarrhoea
8%
Nausea
8%
Vomiting
8%
Chest discomfort
100%
80%
60%
40%
20%
0%
Study treatment Arm
AZD9668
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AZD9668 active treatmentExperimental Treatment1 Intervention
Group II: AZD9668 placebo treatmentPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alvelestat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,403 Previous Clinical Trials
289,124,971 Total Patients Enrolled
2 Trials studying Bronchiectasis
183 Patients Enrolled for Bronchiectasis
Stockley, ProfPrincipal InvestigatorQueen Elizabeth Hospital, Birmingham, England
Carin JorupStudy DirectorAstraZeneca R&D Lund
6 Previous Clinical Trials
12,607 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top